<DOC>
	<DOCNO>NCT00086866</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . PURPOSE : This randomized phase II trial study two different regimen vaccine therapy comparing see well work treat patient stage III stage IV melanoma remove surgery .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage III Stage IV Melanoma That Can Be Removed With Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare objective response rate ( complete partial response ) patient unresectable stage III stage IV M1a cutaneous melanoma immunize vaccine comprise D1/3-MAGE-3-His fusion protein SB-AS02B adjuvant v SB-AS15 adjuvant . - Compare activity SB-AS02B adjuvant v SB-AS15 adjuvant , term maximize antigenicity MAGE-3 , patient treat regimen . - Compare rate grade 3/4 vaccine-related toxicity patient treat regimen . Secondary - Compare progression-free survival patient treat regimen . OUTLINE : This randomize , open label , parallell-group , multicenter study . Patients stratify accord disease stage ( III transit v stage III v IV ) , presence lesion ≥ 20 mm ( yes v ) , participate center . Patients randomize 1 2 treatment arm . - Induction therapy - Arm I : Patients receive immunization comprise D1/3-MAGE-3-His fusion protein SB-AS02B adjuvant intramuscularly ( IM ) weekly week 1 , 3 , 5 , 7 , 9 , 11 . - Arm II : Patients receive immunization comprise D1/3-MAGE-3-His fusion protein SB-AS15 adjuvant IM weekly week 1 , 3 , 5 , 7 , 9 , 11 . Patients achieve clinical complete response ( CR ) , partial response ( PR ) , stable disease ( SD ) , slow progressive disease ( SPD ) proceed maintenance therapy . - Maintenance therapy : Patients arm receive immunization ( accord randomize arm ) weekly week 15 , 18 , 21 , 24 , 27 , 30 , 34 , 40 , 46 , 52 . Patients maintain CR , PR , SD proceed long-term treatment . - Long-term treatment : Beginning 3 month completion maintenance therapy , patient arm receive immunization ( accord randomize arm ) every 3 month 4 course every 6 month 4 course . Treatment continue arm absence disease progression correspond SPD status , unacceptable toxicity , diagnosis autoimmune disease . Patients follow every 12 week . PROJECTED ACCRUAL : A total 68 patient ( 34 patient per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cutaneous melanoma Unresectable stage III OR stage IV M1a disease Documented progressive disease within past 12 week Measurable disease Skin , soft tissue , lymph node metastasis allow provided disease amenable curative treatment surgery Tumor must express MAGE3 gene reverse transcription polymerase chain reaction analysis ( 1 % positive MAGE3 control include assay ) No visceral metastasis within past 56 day image PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Hemoglobin ≥ low limit normal ( LLN ) WBC ≥ LLN Lymphocyte count ≥ LLN Platelet count ≥ LLN No bleed disorder Hepatic Bilirubin ≤ upper limit normal ( ULN ) Lactic dehydrogenase ≤ ULN AST ALT ≤ 2 time ULN PT aPTT normal Hepatitis B surface antigen negative ( antibody test may positive ) Hepatitis C antibody negative Renal Creatinine ≤ ULN Cardiovascular No clinically significant heart disease ( CTC grade III IV ) Immunologic No autoimmune disease ( vitiligo allow ) No antinuclear antibody titer ≥ 1/320 OR equal 1/160 AND autoantibody direct specific autoantigens No immunodeficiency No active infection require antibiotic therapy HIV negative Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No malignancy within past 5 year except surgically cure basal cell squamous cell skin cancer carcinoma situ cervix No serious acute chronic illness require concurrent medication No psychological , familial , sociological , geographical condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy More 8 week since prior adjuvant vaccine therapy No prior vaccine therapy contain MAGE3 antigen No prior vaccine therapy metastatic melanoma No concurrent immunomodulating agent ( e.g. , BCG ) Chemotherapy No prior systemic chemotherapy No concurrent chemotherapy Endocrine therapy No concurrent corticosteroid Concurrent prednisone equivalent allow provide dose ≤ 40 mg/day treatment duration 3 week Concurrent inhale topical steroid allow Radiotherapy No prior radiotherapy spleen No concurrent radiotherapy &gt; 20 % exist lesion ( i.e. , target lesion , nontarget lesion , nonmeasurable lesion ) Concurrent local lowdose ( ≤ 20 Grays ) radiotherapy allow Surgery Recovered prior surgery biopsy No prior organ allograft No prior splenectomy Concurrent surgery limit number lesion allow patient complete response , partial response , stable disease least 3 course study therapy Other No prior systemic anticancer therapy More 4 week since prior isolate limb perfusion therapy No concurrent anticancer therapy No concurrent immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>